SNF472, a novel inhibitor of vascular calcification, could be administered during hemodialysis to attain potentially therapeutic phytate levels

Background: Cardiovascular calcification (CVC) is a major concern in hemodialysis (HD) and the loss of endogenous modulators of calcification seems involved in the process. Phytate is an endogenous crystallization inhibitor and its low molecular mass and high water solubility make it potentially dia...

Descripción completa

Detalles Bibliográficos
Autores: Perello, Joan, Gomez, M, Ferrer, MD, Rodriguez, NY, Salcedo, C, Buades-Fuster, Juan Manuel, Perez, MM, Torregrosa, JV, Martin, E, Maduell, F
Tipo de recurso: artículo
Fecha de publicación:2018
País:España
Institución:Instituto de Salud Carlos III (ISCIII)
Repositorio:Repisalud
Idioma:inglés
OAI Identifier:oai:repisalud.isciii.es:20.500.12105/22614
Acceso en línea:https://hdl.handle.net/20.500.12105/22614
Access Level:acceso abierto
Palabra clave:Cardiovascular calcification
End-stage renal disease
Hemodialysis
Phytate
Diálisis Renal
Ácido Fítico
Soluciones para Diálisis
Humanos
Calcio
Creatinina
Calcificación Vascular
Hemodiafiltración
Vascular Calcification
Hemodiafiltration
Phytic Acid
Creatinine
Calcium
Humans
Renal Dialysis
Dialysis Solutions
Descripción
Sumario:Background: Cardiovascular calcification (CVC) is a major concern in hemodialysis (HD) and the loss of endogenous modulators of calcification seems involved in the process. Phytate is an endogenous crystallization inhibitor and its low molecular mass and high water solubility make it potentially dialyzable. SNF472 (the hexasodium salt of phytate) is being developed for the treatment of calciphylaxis and CVC in HD patients. We aimed to verify if phytate is lost during dialysis, and evaluate SNF472's behaviour during dialysis. Methods: Dialyzability was assessed in vitro using online-hemodiafiltration and high-flux HD systems in blood and saline. SNF472 was infused for 20 min and quantified at different time points. Results Phytate completely dialyzed in 1 h at low concentrations (10 mg/l) but not when added at 30 or 66.67 mg/l SNF472. In bypass conditions, calcium was slightly chelated during SNF472 infusion but when the system was switched to dialysis mode the calcium in the bath compensated this chelation. Conclusion: Phytate dialyses with a low clearance. The administration of SNF472 as an exogenous source of phytate allows to attain supra-physiological levels required for its potential therapeutic properties. As SNF472 is infused during the whole dialysis session, the low clearance would not affect the drug's systemic exposure.